507 related articles for article (PubMed ID: 31212178)
61. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
[TBL] [Abstract][Full Text] [Related]
62. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.
Abou-Zied HA; Youssif BGM; Mohamed MFA; Hayallah AM; Abdel-Aziz M
Bioorg Chem; 2019 Aug; 89():102997. PubMed ID: 31136902
[TBL] [Abstract][Full Text] [Related]
63. Design, synthesis and
Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
[TBL] [Abstract][Full Text] [Related]
64. Synthesis and in vitro antitumor evaluation of new thieno[2,3-d]pyrimidine derivatives as EGFR and DHFR inhibitors.
Fouad MM; Ghabbour HA; Shehata IA; El-Ashmawy MB
Bioorg Chem; 2024 Jul; 148():107401. PubMed ID: 38749115
[TBL] [Abstract][Full Text] [Related]
65. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
66. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
[TBL] [Abstract][Full Text] [Related]
67. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
[TBL] [Abstract][Full Text] [Related]
68. Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents.
Abd El-Karim SS; Anwar MM; Mohamed NA; Nasr T; Elseginy SA
Bioorg Chem; 2015 Dec; 63():1-12. PubMed ID: 26368040
[TBL] [Abstract][Full Text] [Related]
69. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
Soliman AM; Alqahtani AS; Ghorab M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
[TBL] [Abstract][Full Text] [Related]
70. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
71. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
Metwally NH; Mohamed MS; Ragb EA
Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
[TBL] [Abstract][Full Text] [Related]
72. Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma.
Boraei ATA; Ashour HK; El Tamany ESH; Abdelmoaty N; El-Falouji AI; Gomaa MS
Bioorg Chem; 2019 Apr; 85():293-307. PubMed ID: 30654221
[TBL] [Abstract][Full Text] [Related]
73. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
Zhang B; Liu Z; Xia S; Liu Q; Gou S
Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672
[TBL] [Abstract][Full Text] [Related]
74. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
75. Design, Synthesis and Biological Evaluation of Benzohydrazide Derivatives Containing Dihydropyrazoles as Potential EGFR Kinase Inhibitors.
Wang HC; Yan XQ; Yan TL; Li HX; Wang ZC; Zhu HL
Molecules; 2016 Aug; 21(8):. PubMed ID: 27527130
[TBL] [Abstract][Full Text] [Related]
76. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
77. Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents.
Hisham M; Youssif BGM; Osman EEA; Hayallah AM; Abdel-Aziz M
Eur J Med Chem; 2019 Aug; 176():117-128. PubMed ID: 31108261
[TBL] [Abstract][Full Text] [Related]
78. Synthesis of novel 1,2-bis-quinolinyl-1,4-naphthoquinones: ERK2 inhibition, cytotoxicity and molecular docking studies.
Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Brown AB; Bräse S; Nieger M; Ibrahim MAA
Bioorg Chem; 2018 Dec; 81():700-712. PubMed ID: 30268050
[TBL] [Abstract][Full Text] [Related]
79. Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents.
Philoppes JN; Lamie PF
Bioorg Chem; 2019 Aug; 89():102978. PubMed ID: 31136900
[TBL] [Abstract][Full Text] [Related]
80. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
Aziz MW; Kamal AM; Mohamed KO; Elgendy AA
Bioorg Med Chem Lett; 2021 Jun; 41():127987. PubMed ID: 33771586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
